Tag Giuseppe Viscardi

Immunotherapy

CLINICAL PEARLS In patients with no contraindications, immunotherapy monotherapy or its use as part of combination therapy is the mainstay of treatment in non−small cell lung cancer (NSCLC). Testing for PD-L1 expression is essential to help guide treatment decisions. Unlike…